Unfortunately, little in vitro data is available for the effects of capmatinib on head and neck cell lines; however, it is known to be a potent inhibitor of c-MET in a kinase assay (enzymatic IC50 0.13 nM) and proliferation of other tumor lines (cell IC50 1.2–12.4 nM) [114]. Here, MET is linked to neoplasm.